leadf
logo-loader
viewCanntab Therapeutics Ltd
(
CSE:PILLOTCQB:CTABF
)

Canntab Therapeutics received purchase order from Australia while also taking part in research study

Canntab Therapeutics (CSE: PILL-OTCQB: CTABF) CFO Richard Goldstein joined Steve Darling from Proactive Vancouver with news the company has announced the launch of its suite of hard pill cannabinoid formulations in Australia with its partner CANN Global Ltd.

Goldstein takes Proactive through the first deal of the company overseas and he also shares news Canntab will be taking part in Australia's largest observational study ever undertaken for medical cannabis.

Quick facts: Canntab Therapeutics Ltd

Follow
CSE:PILL

Price: 0.72 CAD

Market Cap: $25.6 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Canntab Therapeutics granted 3rd patent while also taking part in large...

Canntab Therapeutics (CSE: PILL- OTCQB: CTABF) CFO Richard Goldstein joined Steve Darling from Proactive with news the Australian Patent Office has granted Canntab an Australian Patent related to its proprietary cannabidiol formulations. Goldstein talks about another validation of their...

on 9/3/21

2 min read